Boosting anticancer vaccines: Too much of a good thing?

Alessia Ricupito, Matteo Grioni, Arianna Calcinotto, Matteo Bellone

Research output: Contribution to journalArticlepeer-review

Abstract

Using both transplantable and oncogene-driven autochthonous tumor models challenged with dendritic cell-based vaccines, we have recently found that boosting provides a clear advantage in prophylactic settings, unless performed on an excessively tight schedule, which causes the loss of central memory T cells. In therapeutic settings, boosting turned out to be always detrimental.

Original languageEnglish
Article numbere25032
JournalOncoImmunology
Volume2
Issue number7
DOIs
Publication statusPublished - 2013

Keywords

  • Adjuvant
  • B16
  • Cancer
  • Cytotoxic T lymphocytes
  • Melanoma
  • Memory
  • Prostate cancer
  • T cell
  • TRAMP
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint

Dive into the research topics of 'Boosting anticancer vaccines: Too much of a good thing?'. Together they form a unique fingerprint.

Cite this